PHASE Scientific | June 22, 2020
PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The study presented by MD Anderson Cancer Center evaluates the efficacy of PHASE Scientific's liquid phase DNA isolation method (PHASIFY™) in improving cancer liquid biopsy sensitivity.Early-stage cancer diagnostics and cancer screening applications are limited by low yields of extracted cell-free DNA (cfDNA) from plasma samples. PHASE Scientific has developed a novel liquid phase DNA isolation method that leverages aqueous two-phase systems (ATPS) to purify and concentrate circulating cfDNA, which can result in increased cfDNA recovery and improved mutant signal detection."PHASE Scientific's technology has shown a significant improvement against conventional solid phase methods for extracting circulating cell-free tumor DNA," says presenter Dr. Filip Janku, MD, Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center. "The ability to enable such an increase of cfDNA yield in patient plasma samples is vital for improving downstream molecular diagnostic sensitivity, efficiency, and cost."The study compared cfDNA recovery and mutation detection from plasma samples extracted with a conventional solid phase method (QIAamp Circulating Nucleic Acid kit - QCNA) and our liquid phase method (PHASIFY™ MAX cfDNA extraction kit). 89 plasma samples from patients with diverse advanced cancers with known BRAF, KRAS or NRAS mutation status were tested.
CELL AND GENE THERAPY
Shoreline Biosciences | November 02, 2021
Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapies, today announced the completion of a $140M financing, led by Ally Bridge Group, with participation from new investors Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, and Superstring. Existing investors Boxer Capital, BVF Partners, L.P., Commodore Capital, Cormorant Asset Management, Janus Henderson Investors, Kite, a Gilead Company, Stork Capital, Wedbush Healthcare Partners and an undisclosed leading global investment firm, also participated. In connection with the financing, Frank Yu, Founder, CEO and CIO of Ally Bridge Group, joined the Shoreline Board of Directors.
"We are proud of Shoreline's tremendous progress over the past year, including next generation, more persistent and more effective iPSC-derived NK cells, enhancing our core technologies, advancing our preclinical programs, establishing transformative and validating partnerships with Kite and BeiGene, creating smart manufacturing methods, and attracting exceptional talent to support our next phase of development and growthWith this financing and our corporate partnerships, Shoreline has now more than $300 million to continue building our pipeline of safe, effective and affordable cellular immunotherapies for both solid tumors and hematologic malignancies."
Kleanthis G. Xanthopoulos, Ph.D., Shoreline's co-founder, Chairman and Chief Executive Officer
"Having invested in – and followed closely for several years -- the iPSC-derived NK cells-based therapeutics field which has made highly encouraging progress in the clinic, we are convinced of the true differentiation demonstrated by the Shoreline technology platform. Ally Bridge Group, a leading investor in best-in-class cell therapy companies from oncology to autoimmune diseases, expects Shoreline to be a new category leader," said Frank Yu, Founder, CEO and CIO of Ally Bridge Group.
The proceeds from the financing will allow Shoreline to continue the advancement of its proprietary iPSC platform focused on developing next generation natural killer (NK) cell and macrophage-cell therapies, create potent and persistent NK cell-specific Chimeric Antigen Receptors (CARs) as well as switchable CAR-NK cell engagers and macrophage-specific CARs to treat blood cancers, solid tumors, and other health conditions. With the close of this financing, Shoreline is well-capitalized with greater than $300 million, including committed partnership R&D funding, to execute on its goals and advance its pipeline.
About Shoreline Biosciences
Shoreline is dedicated to creating next-generation cellular immunotherapies for cancer that overcome the current limitations of first-generation cell therapy products. Shoreline is building a pipeline of natural killer cell and macrophage-cell therapy candidates derived from its deep expertise in iPSC differentiation methods and genetic reprogramming of disease relevant pathways. Shoreline has strategic partnerships with Kite, a Gilead Company, and BeiGene, a global biotechnology company, Contract Development and Manufacturing Organization partnerships with well-established organizations, and is supported by high-quality investors. Shoreline Biosciences is headquartered in San Diego, CA.
PR Newswire | August 21, 2020
CDI Laboratories, Inc. announced the addition of its SARS-CoV-2 (COVID19) assay platform. The assays use CDI's VirScan service which can detect antibodies to 1345 individual viral strains representing species from 76 viral genera. This is coupled with CDI's 2 in 1 SARS-CoV-2 antigen microarray which contains overlapping SARS-CoV-2 peptides as well as full-length proteins. This will allow researchers, therapeutic developers, and vaccine developers, to analyze human serum for all known viruses as well as epitope level data on COVID19 antibodies. In addition, CDI has added the COVID19 S and N proteins to CDI's HuProtTM proteome microarray. CDI's VirScan is the first commercial use of the incredibly powerful PhIP-seq technology (Xu, George J et al. SARS-COV-2 "Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome." Science (New York, N.Y.) vol. 348,6239 (2015): aaa0698. doi:10.1126/science.aaa0698). These p